[Pharmacogenetic-based risk assessment of antipsychotic-induced extrapyramidal symptoms].

摘要: "Typical" antipsychotics remain the wide-prescribed drugs in modern psychiatry. But these are associated with development of extrapyramidal symptoms (EPS). Preventive methods EPS actively developed and they concentrate on personalized approach. The method taking into account genetic characteristics patient for prescribing treatment was proven as effective cardiology, oncology, HIV-medicine. In this review state pharmacogenetic research antipsychotic-induced considered. There pharmacokinetic pharmacodynamic factors which impact adverse effects. Pharmacokinetic most well-studied to date, include polymorphisms genes cytochrome P450. However, evidence base while does not allow do significant prognosis based testing CYP2D6 CYP7A2 polymorphisms. Genes pharmacodynamics factors, realize during antipsychotic treatment, wide field research. separate part such systems dopaminergic, serotonergic, adrenergic, glutamatergic, GABAergic, BDNF were analyzed. role oxidative stress pathogenesis enough detailed system those may be used risk assessment antipsychotics' safety future. Although there numerous studies, pharmacogenetic-based prevention before introduced. it is possible distinguish perspectives markers further Furthermore, brief new candidate provides here, but only preliminary results published. main problem lack high- quality studies. Moreover, several replicated repeat must standardized by ethnicity patients. ethnical misbalance world literature. These facts explain why introduction so difficult achieve.